Sanofi Stock 12‑Month Price Target Cut to $50, Implies 15% Upside
Analyst estimates cited by FactSet show Sanofi’s average 12-month price target was cut to $50 from $50.6. The new range is $45 to $57 per share. Based on the Aug. 7 closing price, the target implies about 15% upside. The consensus rating remains “Buy” with 3 Buys, 4 Holds, and 0 Sells.
How this was made
The 30-second read
Why it matters
A lower consensus price target can influence sentiment and positioning, but the unchanged “Buy” consensus and absence of “Sell” ratings suggest the market impact is likely modest without additional catalysts.
Market read
This is a sentiment/expectations update from analysts, not a new fundamental disclosure.
What to watch
The article does not explain the drivers behind the target reduction, so traders should verify whether any underlying earnings, pipeline, or guidance changes occurred around the same time.
Background
The piece summarizes FactSet-based analyst estimates for Sanofi’s 12-month price target and rating distribution.
Ticker impact
Sanofi’s average 12-month price target was cut from $50.6 to $50, with forecasts spanning $45 to $57 and consensus still “Buy.”
Near-term bias mildly negative to neutral, with follow-through depending on whether more analysts cut targets after this FactSet snapshot.
The article provides a specific target reduction and updated implied upside (~15%) while noting no shift to “Sell” ratings (0 Sells). That combination typically dampens downside but can cap upside expectations.
Market effects
Limited sector read-through because this is a single-name analyst target adjustment without new company fundamentals.
No clear regional spillover indicated beyond European pharma sentiment.
Minimal global relevance; this is not a macro or regulatory catalyst.
Counterpoint
Target cuts may reflect methodology or analyst model updates rather than deteriorating fundamentals, so the market may largely ignore it if no new operating news follows.
Key entities
- companySanofi
Subject of the article, with its average 12-month price target cut to $50 and consensus rating still “Buy.”
